【加科思-B(01167.HK)：SHP2抑制劑SITNEPROTAFIB聯用研究數據發表於學術期刊】加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。

金融界

昨天

加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2534119680"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534119680\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2534119680?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-09 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534119680","market":"hk","top_or_hot":-1,"title":"【加科思-B(01167.HK)：SHP2抑制劑SITNEPROTAFIB聯用研究數據發表於學術期刊】加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。","media":"金融界","content":"<html><body><div><a href=\"https://laohu8.com/S/01167\">加科思-B</a>(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【加科思-B(01167.HK)：SHP2抑制劑SITNEPROTAFIB聯用研究數據發表於學術期刊】加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【加科思-B(01167.HK)：SHP2抑制劑SITNEPROTAFIB聯用研究數據發表於學術期刊】加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金融界</strong><span class=\"h-time small\">2025-05-09 06:46</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div><a href=\"https://laohu8.com/S/01167\">加科思-B</a>(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://24h.jrj.com.cn/2025/05/09064650243257.shtml\">金融界</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"應用軟件","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/05/09064650243257.shtml","article_id":"2534119680","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534119680","pubTimestamp":1746744399,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4023":"应用软件","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","01167":"加科思-B","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK1574":"生物医药B类股","PD":"PagerDuty, Inc.","BK1161":"生物科技"},"translate_title":"[Garcos-B (01167. HK): SHP2 inhibitor sitneprotafib combination research data published in academic journals] Garcos-B (01167. HK) announced that the company's self-developed SHP2 inhibitor sitneprotafib (JAB-3312) related research is published in Clinical Cancer Research (\"Clinical Oncology Research\"). The article announced preclinical in vitro and in vivo data in combination therapies of SHP2 inhibitors and PD-1 antibodies and targeting RTK/RAS/MAPK pathways and representative patient cases who responded to combination therapies.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1,"PD":1},"content_text":"加科思-B(01167.HK)發佈公告，公司自主研發的SHP2抑制劑sitneprotafib (JAB-3312)相關研究見刊Clinical Cancer Research(《臨牀腫瘤研究》)。文章公佈了SHP2抑制劑與PD-1抗體以及靶向RTK/RAS/MAPK通路的聯合療法中的臨牀前體內外數據和對聯合療法有回應的代表性患者病例。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}